Inherited bone marrow failure in the pediatric patient.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
11 08 2022
Historique:
received: 09 10 2020
accepted: 17 12 2020
pubmed: 24 5 2022
medline: 16 8 2022
entrez: 23 5 2022
Statut: ppublish

Résumé

Inherited bone marrow (BM) failure syndromes are a diverse group of disorders characterized by BM failure, usually in association with ≥1 extrahematopoietic abnormalities. BM failure, which can involve ≥1 cell lineages, often presents in the pediatric age group. Furthermore, some children initially labeled as having idiopathic aplastic anemia or myelodysplasia represent cryptic cases of inherited BM failure. Significant advances in the genetics of these syndromes have been made, identifying more than 100 disease genes, giving insights into normal hematopoiesis and how it is disrupted in patients with BM failure. They have also provided important information on fundamental biological pathways, including DNA repair: Fanconi anemia (FA) genes; telomere maintenance: dyskeratosis congenita (DC) genes; and ribosome biogenesis: Shwachman-Diamond syndrome and Diamond-Blackfan anemia genes. In addition, because these disorders are usually associated with extrahematopoietic abnormalities and increased risk of cancer, they have provided insights into human development and cancer. In the clinic, genetic tests stemming from the recent advances facilitate diagnosis, especially when clinical features are insufficient to accurately classify a disorder. Hematopoietic stem cell transplantation using fludarabine-based protocols has significantly improved outcomes, particularly in patients with FA or DC. Management of some other complications, such as cancer, remains a challenge. Recent studies have suggested the possibility of new and potentially more efficacious therapies, including a renewed focus on hematopoietic gene therapy and drugs [transforming growth factor-β inhibitors for FA and PAPD5, a human poly(A) polymerase, inhibitors for DC] that target disease-specific defects.

Identifiants

pubmed: 35605178
pii: S0006-4971(22)00689-9
doi: 10.1182/blood.2020006481
pmc: PMC9373017
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

556-570

Subventions

Organisme : Medical Research Council
ID : MR/P018440/1
Pays : United Kingdom

Informations de copyright

© 2022 by The American Society of Hematology.

Références

Am J Hum Genet. 2015 Jun 4;96(6):1001-7
pubmed: 26046368
Haematologica. 2018 Jul;103(7):e284-e287
pubmed: 29519864
Science. 2002 Jul 26;297(5581):606-9
pubmed: 12065746
Sci Transl Med. 2016 Aug 10;8(351):351ra107
pubmed: 27510903
Curr Opin Allergy Clin Immunol. 2013 Dec;13(6):596-606
pubmed: 24145314
Am J Hum Genet. 2013 May 2;92(5):800-6
pubmed: 23623386
Nat Genet. 1999 Feb;21(2):169-75
pubmed: 9988267
Cell Stem Cell. 2016 May 5;18(5):668-81
pubmed: 27053300
Ann Hematol. 2017 Aug;96(8):1389-1397
pubmed: 28623394
Nat Genet. 2010 May;42(5):406-9
pubmed: 20400963
Hum Mutat. 2012 Jul;33(7):1037-44
pubmed: 22431104
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3132-6
pubmed: 10077649
Nat Genet. 1998 May;19(1):32-8
pubmed: 9590285
Haematologica. 2010 Aug;95(8):1300-7
pubmed: 20435624
Nat Genet. 2007 Jan;39(1):86-92
pubmed: 17187068
Cell Stem Cell. 2020 Jun 4;26(6):896-909.e8
pubmed: 32320679
Nat Genet. 2003 Jul;34(3):308-12
pubmed: 12778173
Hum Mol Genet. 2010 Nov 15;19(22):4453-61
pubmed: 20817924
Expert Rev Hematol. 2017 Jan;10(1):81-97
pubmed: 27929686
Br J Haematol. 2005 Nov;131(4):431-46
pubmed: 16281933
Blood. 2013 Sep 26;122(13):2162-6
pubmed: 23940284
Nature. 2001 Sep 27;413(6854):432-5
pubmed: 11574891
Hum Genet. 2013 Nov;132(11):1265-74
pubmed: 23812780
Blood Rev. 2010 May;24(3):101-22
pubmed: 20417588
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15960-4
pubmed: 16247010
Nat Genet. 2009 Aug;41(8):936-40
pubmed: 19561605
Nat Commun. 2020 Feb 25;11(1):1044
pubmed: 32098966
Nat Genet. 2019 Oct;51(10):1518-1529
pubmed: 31570891
Nat Rev Genet. 2007 Oct;8(10):735-48
pubmed: 17768402
Hum Mutat. 2007 Dec;28(12):1178-82
pubmed: 17647292
Am J Hum Genet. 2008 Dec;83(6):769-80
pubmed: 19061985
Helv Med Acta. 1968 Mar;34(2):103-15
pubmed: 5658197
Sci Adv. 2020 Apr 10;6(15):eaay3511
pubmed: 32300648
Nat Genet. 2004 Nov;36(11):1219-24
pubmed: 15502827
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2561-2570
pubmed: 30692263
Angiogenesis. 2019 Feb;22(1):95-102
pubmed: 30168024
N Engl J Med. 2013 Jul 4;369(1):54-65
pubmed: 23738510
Hum Mol Genet. 2008 May 1;17(9):1253-63
pubmed: 18230666
Adv Biol Regul. 2018 Jan;67:109-127
pubmed: 28942353
Br J Haematol. 2000 Sep;110(4):768-79
pubmed: 11054058
Am J Hum Genet. 2000 Nov;67(5):1306-8
pubmed: 11001585
Nat Genet. 2000 Jan;24(1):15-6
pubmed: 10615118
PLoS One. 2009 Nov 20;4(11):e7926
pubmed: 19936245
Blood Cells Mol Dis. 2012 Feb 15;48(2):128-31
pubmed: 22178060
Proc Natl Acad Sci U S A. 2018 Jul 24;115(30):7777-7782
pubmed: 29987015
Am J Hum Genet. 2010 Nov 12;87(5):721-7
pubmed: 21055716
Nat Genet. 2003 Jan;33(1):97-101
pubmed: 12496757
Nat Genet. 1996 Nov;14(3):320-3
pubmed: 8896563
Curr Opin Genet Dev. 2015 Aug;33:32-40
pubmed: 26254775
Bone Marrow Transplant. 2003 Oct;32(7):653-6
pubmed: 13130311
Bone Marrow Transplant. 2011 Jan;46(1):98-104
pubmed: 20383216
Mol Cell. 2001 Feb;7(2):241-8
pubmed: 11239453
Blood. 2015 Oct 15;126(16):1885-92; quiz 1970
pubmed: 26185129
Am J Hum Genet. 2013 Mar 7;92(3):448-53
pubmed: 23453664
Nat Genet. 2007 Feb;39(2):162-4
pubmed: 17200671
Nat Genet. 2011 Feb;43(2):138-41
pubmed: 21240277
Hum Mutat. 2009 Nov;30(11):1567-73
pubmed: 19760749
J Clin Invest. 2015 May;125(5):2151-60
pubmed: 25893599
Blood. 2003 Sep 15;102(6):2053-9
pubmed: 12750172
Blood. 2007 Sep 1;110(5):1439-47
pubmed: 17468339
Br J Haematol. 1969 Jul;17(1):11-26
pubmed: 5807784
Nature. 1999 Dec 2;402(6761):551-5
pubmed: 10591218
J Clin Invest. 2017 Aug 1;127(8):3013-3027
pubmed: 28691929
Blood. 2018 Feb 15;131(7):717-732
pubmed: 29146883
Nature. 2018 Jan 11;553(7687):171-177
pubmed: 29323295
Blood Cells Mol Dis. 2001 Mar-Apr;27(2):353-7
pubmed: 11259155
Nat Med. 2019 Sep;25(9):1396-1401
pubmed: 31501599
Hum Mol Genet. 2007 Jul 1;16(13):1619-29
pubmed: 17507419
Br J Haematol. 1999 Nov;107(2):335-9
pubmed: 10583221
N Engl J Med. 2005 Apr 7;352(14):1413-24
pubmed: 15814878
J Clin Invest. 2012 Jul;122(7):2439-43
pubmed: 22706301
Nat Chem Biol. 2007 Oct;3(10):640-9
pubmed: 17876321
J Med Genet. 2011 Sep;48(9):618-28
pubmed: 21659346
Blood. 2008 Sep 1;112(5):1582-92
pubmed: 18535205
Haematologica. 2019 Aug;104(8):e335-e339
pubmed: 30679331
Br J Haematol. 2014 Jun;165(5):673-81
pubmed: 24611452
Lancet. 2002 Jun 22;359(9324):2168-70
pubmed: 12090986
Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8073-8
pubmed: 18523010
Nature. 1992 Apr 30;356(6372):763-7
pubmed: 1574115
Br J Haematol. 2018 Oct;183(1):110-118
pubmed: 29984823
Am J Hum Genet. 2008 Feb;82(2):501-9
pubmed: 18252230
Am J Med Genet A. 2017 Apr;173(4):1017-1037
pubmed: 28168833
N Engl J Med. 2007 Mar 29;356(13):1317-26
pubmed: 17392301
Blood. 2013 Jun 6;121(23):4791-9
pubmed: 23570799
Am J Hum Genet. 2002 Dec;71(6):1467-74
pubmed: 12434312
Nat Genet. 1998 Nov;20(3):281-3
pubmed: 9806548
J Pathol. 2012 Jan;226(2):326-37
pubmed: 21956823
Genes Dev. 2019 Oct 1;33(19-20):1381-1396
pubmed: 31488579
Pediatr Blood Cancer. 2006 May 1;46(5):558-64
pubmed: 16317735
Am J Hum Genet. 2010 Feb 12;86(2):222-8
pubmed: 20116044
Hematol Oncol Clin North Am. 2009 Apr;23(2):307-20
pubmed: 19327585
N Engl J Med. 2009 Jan 1;360(1):32-43
pubmed: 19118303
Blood. 2000 Oct 1;96(7):2317-22
pubmed: 11001877
Haematologica. 2013 Sep;98(9):1383-7
pubmed: 23716552
Genes Dev. 2011 Jan 1;25(1):11-6
pubmed: 21205863
Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1187-92
pubmed: 19147845
J Pediatr. 1964 Nov;65:645-63
pubmed: 14221166
Nat Genet. 2005 Sep;37(9):934-5
pubmed: 16116423
Am J Hum Genet. 2018 Dec 6;103(6):930-947
pubmed: 30503522
Blood. 2007 Dec 15;110(13):4198-205
pubmed: 17785587
Br J Haematol. 2002 Sep;118(3):701-13
pubmed: 12181037
N Engl J Med. 2016 May 19;374(20):1922-31
pubmed: 27192671
Cell. 2007 Apr 20;129(2):289-301
pubmed: 17412408
J Clin Invest. 2017 Mar 1;127(3):1117
pubmed: 28248207

Auteurs

Inderjeet Dokal (I)

Centre for Genomics and Child Health, Blizard Institute, London, United Kingdom; and.
Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Barts Health National Health Service (NHS) Trust, London, United Kingdom.

Hemanth Tummala (H)

Centre for Genomics and Child Health, Blizard Institute, London, United Kingdom; and.
Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Barts Health National Health Service (NHS) Trust, London, United Kingdom.

Tom Vulliamy (T)

Centre for Genomics and Child Health, Blizard Institute, London, United Kingdom; and.
Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Barts Health National Health Service (NHS) Trust, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH